Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
News: Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
All NewsEconomyCurrencies & ForexEconomic EventsCryptocurrenciesCybersecurityPress Releases

Sanofi raises profit forecast after second quarter beat

07/29/2021 | 02:44am EDT
FILE PHOTO: Sanofi logo is seen during the company's annual results news conference in Paris, France

PARIS (Reuters) -Sanofi raised its 2021 profit forecast on Thursday after its vaccines and star eczema treatment Dupixent helped it beat second-quarter results expectations.

The French drugmaker said it was now targeting earnings per share growth of around 12% at constant exchange rates this year, up from "high single digit" percentage growth previously.

Sanofi, which shocked investors last year with a delay to a COVID-19 vaccine it is developing with Britain's GlaxoSmithKline, reiterated its confidence in the shot, which it hopes will secure regulatory approval by the end of the year.

Europe's drug regulator said last week it had started a real-time review of the vaccine.

If approved, Sanofi's shot will come long after ones from Pfizer/BioNTech, and Moderna, which have produced efficacy results of more than 90%.

But the French company believes its vaccine could play a significant role in tackling the pandemic, as many parts of the world still have a pressing need for doses.

In countries already rolling out mass vaccinations, Sanofi also sees a potential role for the shot as a booster, as many regulators contemplate recommending a third dose to extend protection.

So far, Sanofi has purchasing agreements with the United States, the European Union, Britain and Canada, as well as with the World Health Organization-backed COVAX facility.

The company has also pledged to help other COVID-19 vaccine makers this year, striking "fill and finish" deals for shots made by Pfizer/BioNTech, Moderna and Johnson & Johnson.

Sales of Dupixent, which is sold to patients with eczema but also prescribed for other conditions such as asthma, jumped 57% to 1.24 billion euros ($1.47 billion).

Revenue at the vaccines unit was up 16.2% to 1 billion euros, helped by stronger demand for booster and meningitis shots.

Overall, Sanofi's sales rose 12.4% in the second quarter to 8.74 billion euros, while business net income - a figure the company uses as its core metric to measure profits - was up 16.8% to 1.73 billion euros.

Analysts polled by Refinitiv had on average been expecting sales of 8.5 billion euros and net income of 1 billion euros.

($1 = 0.8436 euros)

(Reporting by Matthias BlamontEditing by Jacqueline Wong and Mark Potter)

By Matthias Blamont


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
GLAXOSMITHKLINE PLC -0.96% 1398.6 Delayed Quote.5.37%
MODERNA, INC. 3.15% 454.6 Delayed Quote.335.15%
Latest news "Economy & Forex"
05:00aAlarmed by Evergrande, China's lenders hold back on new credit for property developers
RE
04:58aEurostoxx 50 : European shares fall on Evergrande fears but hold weekly gains
RE
04:52aCHINA EVERGRANDE : Sterling dips after rally triggered by hawkish BoE
RE
04:52aKakao Pay pushes back planned $1.3 billion IPO to November
RE
04:50aGlobal equity funds see their first outflows in 2021 - BofA
RE
04:46aEuropean stocks slip on Evergrande woes, weak German business morale
RE
04:44aJapan equities shine as foreign investors bet on stimulus, political change
RE
04:40aEUROPE GAS-Prices ease as Norwegian supplies ramp up
RE
04:37aWorld's youth returns to the streets to fight climate change
RE
04:35aItaly business confidence slips in Sept but consumer morale hits record high
RE
Latest news "Economy & Forex"